ATE128623T1 - Mittel zur verbesserung von arzneimitteleffekten für antitumormittel. - Google Patents
Mittel zur verbesserung von arzneimitteleffekten für antitumormittel.Info
- Publication number
- ATE128623T1 ATE128623T1 AT89114113T AT89114113T ATE128623T1 AT E128623 T1 ATE128623 T1 AT E128623T1 AT 89114113 T AT89114113 T AT 89114113T AT 89114113 T AT89114113 T AT 89114113T AT E128623 T1 ATE128623 T1 AT E128623T1
- Authority
- AT
- Austria
- Prior art keywords
- substituted
- alkyl
- mar
- linear
- same meaning
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- -1 2,1,3-benzooxadiazol-4-yl Chemical group 0.000 abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical group C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19300288 | 1988-08-02 | ||
| JP1168549A JP2850376B2 (ja) | 1988-08-02 | 1989-06-30 | 抗癌剤薬効増強剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE128623T1 true ATE128623T1 (de) | 1995-10-15 |
Family
ID=26492212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89114113T ATE128623T1 (de) | 1988-08-02 | 1989-07-31 | Mittel zur verbesserung von arzneimitteleffekten für antitumormittel. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5130303A (de) |
| EP (1) | EP0353692B1 (de) |
| AT (1) | ATE128623T1 (de) |
| CA (1) | CA1334752C (de) |
| DE (1) | DE68924456T2 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8914060D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| WO1990015599A1 (en) * | 1989-06-19 | 1990-12-27 | The Wellcome Foundation Limited | Medicaments useful in cancer therapy and having antihistaminic properties |
| GB8914061D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8914040D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8914062D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| EP0511790A1 (de) * | 1991-04-26 | 1992-11-04 | Ajinomoto Co., Inc. | Gegen Tumorzellen verwendbare 1,4-Dihydropyridinderivate |
| AU5813394A (en) * | 1992-12-23 | 1994-07-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Anellated uracil derivates |
| US5436243A (en) * | 1993-11-17 | 1995-07-25 | Research Triangle Institute Duke University | Aminoanthraquinone derivatives to combat multidrug resistance |
| US5432168A (en) * | 1993-12-27 | 1995-07-11 | University Of Manitoba | Method of treatment of hormone-unresponsive metastatic prostate cancer |
| JP3178843B2 (ja) * | 1995-03-13 | 2001-06-25 | 日研化学株式会社 | イミダゾチアゾール化合物 |
| JP4741725B2 (ja) * | 1998-03-06 | 2011-08-10 | メタベイシス・セラピューティクス・インコーポレーテッド | リン含有化合物のための新規なプロドラッグ |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| JP5063837B2 (ja) * | 1999-03-05 | 2012-10-31 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 新規リン含有プロドラッグ |
| US7205404B1 (en) | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| US6752981B1 (en) | 1999-09-08 | 2004-06-22 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
| US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| US6376514B1 (en) * | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
| WO2004037161A2 (en) | 2002-05-13 | 2004-05-06 | Metabasis Therapeutics, Inc. | Cyclic prodrugs of pmea one of its analogues |
| CA2485597C (en) | 2002-05-13 | 2013-07-02 | Metabasis Therapeutics, Inc. | Process for preparation of cyclic prodrugs of pmea and pmpa |
| JP4125076B2 (ja) * | 2002-08-30 | 2008-07-23 | キヤノン株式会社 | モノアミノフルオレン化合物およびそれを使用した有機発光素子 |
| WO2004041834A2 (en) | 2002-10-31 | 2004-05-21 | Metabasis Therapeutics, Inc. | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
| TW200528107A (en) * | 2003-11-25 | 2005-09-01 | Nissan Chemical Ind Ltd | T-type calcium channel inhibitor |
| CN1281210C (zh) * | 2003-11-29 | 2006-10-25 | 胡汛 | 五味子乙素在制备治疗肿瘤药物中的应用 |
| EP1753762B1 (de) | 2004-06-08 | 2014-03-19 | Metabasis Therapeutics, Inc. | Lewissäurevermittelte synthese von cyclischen estern |
| WO2008137107A1 (en) * | 2007-05-02 | 2008-11-13 | Krouse Andrew J | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| AU2011223883B2 (en) | 2010-03-01 | 2015-10-08 | Cavion, Inc. | Cancer diagnosis and imaging |
| AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| EP3737676B1 (de) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetalverbindungen und therapeutische verwendungen davon |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670827C3 (de) * | 1967-03-20 | 1974-10-24 | Bayer Ag, 5090 Leverkusen | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin |
| US3985758A (en) * | 1973-02-20 | 1976-10-12 | Yamanouchi Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives |
| US4307103A (en) * | 1978-09-08 | 1981-12-22 | Fujisawa Pharmaceutical Co., Ltd. | Dihydropyridine derivative, processes for preparation thereof and pharmaceutical composition comprising the same |
| US4340718A (en) * | 1980-06-02 | 1982-07-20 | Eastman Kodak Company | Stabilized copolyester material |
| JPS59161392A (ja) * | 1983-03-04 | 1984-09-12 | Nippon Shinyaku Co Ltd | ジヒドロピリジン誘導体及びその製法 |
| US4906646A (en) * | 1983-03-31 | 1990-03-06 | Board Of Governors Of Wayne State University | Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class |
| US4690935A (en) * | 1983-03-31 | 1987-09-01 | Wayne State University | Inhibition of tumor growth and metastasis with calcium channel blocker compounds |
| JPS6056956A (ja) * | 1983-09-08 | 1985-04-02 | Shoichiro Ozaki | １，４−ジヒドロピリジン誘導体及びその製法 |
| EP0141221A1 (de) * | 1983-09-26 | 1985-05-15 | Nissan Chemical Industries Ltd. | 1,4-Dihydropyridin-5-Phosphonsäure-Ester |
| EP0141222B1 (de) * | 1983-09-26 | 1989-04-12 | Nissan Chemical Industries Ltd. | Zyklische Dihydropyridin-5-Phosphonsäure-Ester |
| JPS60248693A (ja) * | 1984-04-19 | 1985-12-09 | Nippon Shinyaku Co Ltd | ピリジン誘導体及び製法 |
| JPS6163689A (ja) * | 1984-09-03 | 1986-04-01 | Nippon Shinyaku Co Ltd | ピリジン誘導体 |
| IT1201454B (it) * | 1985-08-19 | 1989-02-02 | Boehringer Biochemia Srl | 1,4-diidropiridine-2-sostituite |
| CN1016063B (zh) * | 1986-01-22 | 1992-04-01 | 日产化学工业株式会社 | 二氢吡啶-5-膦酸环亚丙基酯的制备 |
| US4885284A (en) * | 1986-01-22 | 1989-12-05 | Nissan Chemical Industries Ltd. | Dihydropyridine-5-phosphonic acid cyclic propylene ester |
| JPH0755955B2 (ja) * | 1986-09-10 | 1995-06-14 | 日産化学工業株式会社 | 光学活性なジヒドロピリジン−５−ホスホン酸エステル |
| JPS63115890A (ja) * | 1986-10-31 | 1988-05-20 | Nippon Shinyaku Co Ltd | ２位置換１，４−ジヒドロピリジン誘導体 |
| GB8822170D0 (en) * | 1988-09-21 | 1988-10-26 | Pfizer Ltd | Therapeutic agents |
-
1989
- 1989-07-31 EP EP89114113A patent/EP0353692B1/de not_active Expired - Lifetime
- 1989-07-31 AT AT89114113T patent/ATE128623T1/de not_active IP Right Cessation
- 1989-07-31 CA CA000607026A patent/CA1334752C/en not_active Expired - Fee Related
- 1989-07-31 DE DE68924456T patent/DE68924456T2/de not_active Expired - Fee Related
-
1991
- 1991-07-15 US US07/729,904 patent/US5130303A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0353692B1 (de) | 1995-10-04 |
| DE68924456D1 (de) | 1995-11-09 |
| DE68924456T2 (de) | 1996-05-30 |
| EP0353692A2 (de) | 1990-02-07 |
| EP0353692A3 (de) | 1991-05-08 |
| CA1334752C (en) | 1995-03-14 |
| US5130303A (en) | 1992-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE128623T1 (de) | Mittel zur verbesserung von arzneimitteleffekten für antitumormittel. | |
| DE69501947T2 (de) | SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER | |
| KR960701019A (ko) | 신규의 4-아미노피리딘, 이것의 제조방법 및 이것을 함유하는 약제(new 4-aminopyridines, process for preparing the same and me-dicaments containing the same) | |
| NZ307505A (en) | Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds | |
| RU92004336A (ru) | Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты | |
| DK34793A (da) | Vandoploeseligt, farmaceutisk acceptabelt salt af et monoacylderivat af rapamycin, fremgangsmaade til dets fremstilling og injicerbart, farmaceutisk praeparat indeholdende det | |
| FI905839A (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi | |
| HUT54155A (en) | Process for producing new compounds with purine skeleton and pharmaceutical compositions compriing same | |
| BG98216A (en) | Benzofuran derivatives | |
| ATE140698T1 (de) | Diazotierte heterocyclische derivate aus stickstoff, substituiert durch eine biphenylgruppe, ihre herstellung, und diese enthaltende pharmazeutische zubereitungen | |
| ES2000185A6 (es) | Procedimiento para preparar derivados de acidos piridoncaboxilicos | |
| NZ240050A (en) | Substituted piperazine derivatives; pharmaceutical compositions and preparatory processes | |
| EP0309422A3 (de) | Amidinotricyclische Derivate | |
| ES524236A0 (es) | Un procedimiento para la preparacion de 1,4-dihidropiridina | |
| IL83681A0 (en) | Dihydropyridines,their preparation and pharmaceutical compositions containing them | |
| ES534505A0 (es) | Un procedimiento para la preparacion de compuestos de 1, 4-dihidropiridina | |
| MY118004A (en) | Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| ES8704480A1 (es) | Un procedimiento para la preparacion de derivados de 1,4-dihidropiridina. | |
| NZ335055A (en) | Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumour agents and process for its production | |
| HUT60261A (en) | Process for producing piperazine derivatives and pharmaceutical compositions comprising same | |
| ATE236152T1 (de) | Benzothiophenverbindungen, zwischenprodukte, verfahren und verwendungsmethode | |
| IL115085A0 (en) | Bicyclic carboxamide derivatives their preparation and pharmaceutical compositions containing them | |
| IL85253A0 (en) | Ergoline derivatives,their preparation and pharmaceutical compositions containing them | |
| SE8405338D0 (sv) | (1,3) oxazino (4,3-a) isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them | |
| RU93005288A (ru) | Производные конденсированных гетероциклических кетонов, их получение, использование, фармацевтическая композиция, способ лечения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |